Please assess the completion status of the following clinical trial:

Trial Title: Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 75 year-old women; HER2 negative(immunohistochemistry or fluorescence in situ hybridization);~* ECOG score: 0-1, expected survival time ≥ 3months;~* Pathologically or cytologically confirmed breast cancer;~* Anthracycline- / taxane- pretreated (adjuvant, neoadjuvant) breast cancer patients who have failed from 1-2 standard chemotherapies after recurrence and metastasis;~* According to RECIST 1.1, exist at least ≥1 measurable lesion(CT \>1cm，other examination \>2cm);~* The patients have enough organ function. The laboratory test indexes must comply with the following requirements:~  * Blood routine: neutrophil≥1.5G/L, platelet count ≥80G/L, hemoglobin ≥90g/L~ * Liver function: serum bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST≤2.5 times the upper limit of normal value; ALT and AST≤5 times the upper limit of normal value when liver metastasis~ * Renal function: serum creatinine ≤ 1.0times the upper limit of normal value, creatinine clearance \>50ml/min（Cockcroft-Gault formula)~* Women of child-bearing age should be carried out pregnancy test (serum or urine) within 7 days before recruit, the results should be negative; and are willing to adopt the appropriate methods of contraception during the trial and 8 weeks after last administration；~* Can swallow oral drugs;~* The patients have good compliance to the therapy and follow-up to be scheduled and are able to understand the study protocol and sign the Informed Consent Form.~Exclusion Criteria:~* The patients in pregnancy or lactation growth period and did not take effective contraception;~* The patients who received ≥3 chemotherapies（Do not include endocrine therapy）after recurrence and metastasis; involved in other clinical trials four weeks prior to the start of the study;~* The patients with a variety of factors that affect the oral administration and absorption of drugs;~* The patients previously received anti-VEFG of anti-VEGFR therapies;~* The patients with rapid progression of viscera invasion(liver lesion \>1/2 viscera area or liver dysfunction);~* The patients have uncontrollable mental illness.~* The patients who had serious adverse effect to oral etoposide or were allergic to etoposide.~* The patients who have only bone metastasis without other measurable lesion;~* The patients experience severe cardiovascular diseases;~* The patients experience severe upper gastrointestinal ulcer or malabsorption syndrome.~* Abnormal bone marrow functions(neutrophil\<1.5G/L, platelet count \<75G/L, hemoglobin \<90g/L);~* Abnormal renal function(serum creatinine \> 1.5 times the upper limit of normal value);~* Abnormal liver function(serum bilirubin ≤ 1.5 times the upper limit of normal value);~* The patients have uncontrollable brain metastasis;~* The patients do have good compliance to the therapy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- apatinib+oral etoposide (Type: OTHER): apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).